Literature DB >> 7688949

Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine.

J Meers1, G M del Fierro, R B Cope, H S Park, W K Greene, W F Robinson.   

Abstract

The plasma and peripheral blood mononuclear cell (PBMC) titer of feline immunodeficiency virus (FIV) in experimentally infected cats was assessed following administration of either zidovudine or cyclosporine. Treatments were begun 24 h post infection (p.i.) and continued for 4 weeks. Zidovudine treatment did not prevent establishment of infection with FIV, but plasma virus titers were significantly lower than controls at 2 weeks p.i. This reduction of plasma virus titer by zidovudine was not maintained at subsequent sampling times. Similarly, cyclosporine treatment initially lowered plasma virus titers at 2 weeks p.i., but at 4 weeks p.i. the plasma virus titers in cyclosporine-treated cats were significantly higher than in the untreated group. In the untreated group, plasma virus titers declined rapidly to an undetectable level by 14 weeks p.i. Neither zidovudine or cyclosporine treatment significantly influenced the titer of FIV in PBMCs. In all groups (untreated, zidovudine and cyclosporine) the titers in PBMC were high for the duration of the experiment. The decline in plasma virus titers in immunocompetent cats combined with the effect of cyclosporine on plasma titers strongly suggest that the immune system plays a major role in clearing FIV from plasma. In contrast, it appears that the immune response has little impact on PBMC virus titers. This shows that for complete assessment of antiviral agents, both cell-free and cell-associated virus titers must be examined. We also suggest that the limitation of viral titers in PBMC may be of critical importance in the control of lentiviral infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688949     DOI: 10.1007/bf01309844

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  37 in total

1.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Authors:  C A Boucher; E O'Sullivan; J W Mulder; C Ramautarsing; P Kellam; G Darby; J M Lange; J Goudsmit; B A Larder
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

2.  Comparison of two host cell range variants of feline immunodeficiency virus.

Authors:  T R Phillips; R L Talbott; C Lamont; S Muir; K Lovelace; J H Elder
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.

Authors:  K M Remington; B Chesebro; K Wehrly; N C Pedersen; T W North
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

4.  Feline immunodeficiency virus: quantification in peripheral blood mononuclear cells and isolation from plasma of infected cats.

Authors:  J Meers; W F Robinson; G M del Fierro; M A Scoones; M A Lawson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

5.  Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon-alpha: failure after inoculating rhesus monkeys with a high dose of SIV.

Authors:  F Fazely; W A Haseltine; R F Rodger; R M Ruprecht
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

6.  Surveillance of health care workers exposed to blood from patients infected with the human immunodeficiency virus.

Authors:  R Marcus
Journal:  N Engl J Med       Date:  1988-10-27       Impact factor: 91.245

7.  HIV-1 proviral copy number in blood mononuclear cells from AIDS patients on zidovudine therapy.

Authors:  R M Donovan; R E Dickover; E Goldstein; R G Huth; J R Carlson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

8.  Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection.

Authors:  L E Perryman; K I O'Rourke; T C McGuire
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.

Authors:  E S Daar; T Moudgil; R D Meyer; D D Ho
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

10.  Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner.

Authors:  C C Shih; H Kaneshima; L Rabin; R Namikawa; P Sager; J McGowan; J M McCune
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

View more
  6 in total

Review 1.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

2.  Extensive sequence variation of feline immunodeficiency virus env genes in isolates from naturally infected cats.

Authors:  W K Greene; J Meers; G del Fierro; P R Carnegie; W F Robinson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 3.  Pharmacological inhibition of feline immunodeficiency virus (FIV).

Authors:  Hakimeh Mohammadi; Dorothee Bienzle
Journal:  Viruses       Date:  2012-04-27       Impact factor: 5.048

4.  Cyclophilin A interacts with diverse lentiviral capsids.

Authors:  Tsai-Yu Lin; Michael Emerman
Journal:  Retrovirology       Date:  2006-10-12       Impact factor: 4.602

5.  Immunopathologic Effects of Prednisolone and Cyclosporine A on Feline Immunodeficiency Virus Replication and Persistence.

Authors:  Craig Miller; Jordan Powers; Esther Musselman; Ryan Mackie; John Elder; Sue VandeWoude
Journal:  Viruses       Date:  2019-08-30       Impact factor: 5.048

Review 6.  Feline immunodeficiency virus infection: an overview.

Authors:  K Hartmann
Journal:  Vet J       Date:  1998-03       Impact factor: 2.688

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.